Our preclinical studies suggested that systematically targeting the MCT-1/IL-6/IL-6R/CXCL7/PD-L1 nexus could be a new medical opportunity that would benefit long-term cancer control and disease-free survival. This evidence concerns the gene IL6 and cancer.